{"name":"Dermavant Sciences","slug":"dermavant","ticker":"Private","exchange":"Private","domain":"dermavant.com","description":"Dermavant Sciences is a private biopharmaceutical company focused on dermatology. The company's top drugs include tapinarof, a topical small molecule being developed for the treatment of psoriasis and atopic dermatitis. Dermavant Sciences has a strong pipeline of products in various stages of development.","hq":"Basel, Switzerland / Durham, NC","founded":0,"employees":"","ceo":"Todd Zavodnick","sector":"Dermatology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (Roivant subsidiary)","metrics":{"revenue":320000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"tapinarof patent cliff ($0.00 at risk)","drug":"tapinarof","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cerdulatinib 0.37% gel","genericName":"Cerdulatinib 0.37% gel","slug":"cerdulatinib-0-37-gel","indication":"Atopic dermatitis (topical)","status":"phase_2"}]}],"pipeline":[{"name":"Cerdulatinib 0.37% gel","genericName":"Cerdulatinib 0.37% gel","slug":"cerdulatinib-0-37-gel","phase":"phase_2","mechanism":"Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation.","indications":["Atopic dermatitis (topical)","Alopecia areata (topical)"],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Dermavant Sciences Announces FDA Approval of Tapinarof Cream, 4% for the Treatment of Mild to Moderate Plaque Psoriasis","summary":"The FDA has approved tapinarof cream, 4% for the treatment of mild to moderate plaque psoriasis.","drugName":"tapinarof","sentiment":"positive"},{"date":"2022-05-10","type":"deal","headline":"Dermavant Sciences Announces Collaboration with Pfizer to Develop and Commercialize Tapinarof for Atopic Dermatitis","summary":"Dermavant Sciences has entered into a collaboration with Pfizer to develop and commercialize tapinarof for atopic dermatitis.","drugName":"tapinarof","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQZHUtRUxnM25EUHFmN2J6Y2tsek9VVE9UMUg5YmF4N0xxdG9hQjFhekV2WDlfcC1yU1dycGNjcjNoNHVOcWtnT0pVaU1jSWViQkJKeFlsMlRCSUVSOXVGSTJUaVNsWHllcGVoY0FQUkpRUWtPelV3ekxyVlVieXd3UmtKeDJXbDBmdUYwb1pxYVhpRXM0LVgxYjdyeWQ4ZFZfQjAzTHFvMlF0anNmSm12SGRn?oc=5","date":"2026-02-13","type":"trial","source":"endpoints.news","summary":"Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO - endpoints.news","headline":"Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOSWlhSFNoWkRhMWptMGx5V2prN09oZ2dqRGhRSmRRcG5CSE5uSkR3WkE3ZnB0ZFpDTS1LWVd2UG9PZU1wVHBOdnBJbmRwWVdvUElpbFZ6Z3Zic2pnd2liTVQ5RDVZanQ3MmpXb1RObTJCMHp0RDYxUDlkdG0yUlRLT3V4eFVqWWllMHFNZDlMdGZvRFJSeC05TVRCUlRaekpsYzJ6S3JJVERnZUR4SWdNQ3FvdENtVnBLbzVxSllB?oc=5","date":"2026-02-12","type":"pipeline","source":"Stock Titan","summary":"VTAMA launch leader joins Verrica to drive YCANTH skin treatment - Stock Titan","headline":"VTAMA launch leader joins Verrica to drive YCANTH skin treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQWldBRjJsWjZqUXFPV0dCLVZsclZyc1FyTVpTX1RNamkxRElDZHZxSGRtb3IxTWlBWldXWHUyaGc2aVVpcVE4a1lOUDQwMUE3M1N0X09TU1AtcGhsa1hFSG9KT3E1RFR2M1V5UWctMDZyQzRnM3doU0RTamZIQ1NUUGZaakIxNkE5ZUxtMFlOUXBSR0RKVjl2WnRuTGZWaHJv?oc=5","date":"2024-10-29","type":"pipeline","source":"Pharmaceutical Technology","summary":"Organon expands dermatology portfolio with Dermavant acquisition - Pharmaceutical Technology","headline":"Organon expands dermatology portfolio with Dermavant acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPLWpWWG1zaTh1LVUyM2ZZdDdzOVFBSGtNU2dvWDFoV3RMQnZwY3JXX0s1TFRrTjRHajVqR2otbmdTMEVqN2pTM24yLVU4aC1PNUtUNUdoSTBBVmdGR1doT050cnRNQ0N2RmloS21ubEhZWHJYU2gweF9rRUtvMFBsYmxIcHdyT0VrSGd4Ym5uRWdiWXhYblZjZ05faXM?oc=5","date":"2024-09-18","type":"deal","source":"BioPharma Dive","summary":"Roivant dermatology subsidiary to be acquired by Organon - BioPharma Dive","headline":"Roivant dermatology subsidiary to be acquired by Organon","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-24","type":"pipeline","source":"PR Newswire","summary":"Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant","headline":"Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Laks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNbG9FQlVReTFrazZnbXBBZFBQV2tXZkZ5UjdBSzQ3YkZUeEhzNHV0UkoxR0hGU2RENHZIR1RGMVV2RXZqZ2JpS3gxclNCaHVwVVFTeGNsX0xDSV9naFh1aGRNTkhKLU5JWXExTEhBc0Q1amxHNVdsM28zdnNZRGVGQnBWQnkzOHlvUVhvemp3?oc=5","date":"2018-07-16","type":"pipeline","source":"Pharmaceutical Technology","summary":"GSK to divest tapinarof asset rights to Dermavant for £250m - Pharmaceutical Technology","headline":"GSK to divest tapinarof asset rights to Dermavant for £250m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE01UGpraWY0a1FXV1FOcGtzS0c5MUZwZkFSc3FqSlVDQ0JuWkctUVlHVjVDNjJ3RFRKaEQyclVJU085enpFNDdfVzR4Z08tbmNYb0QwNVdJYXVGQUxlYlRxWkpjMFBINzUyVlVtRFp3?oc=5","date":"2017-09-21","type":"pipeline","source":"Fortune","summary":"How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs - Fortune","headline":"How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs","sentiment":"neutral"}],"patents":[{"drugName":"tapinarof","drugSlug":"tapinarof","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Galderma","L'Oréal","Pfizer"],"therapeuticFocus":["Psoriasis","Atopic Dermatitis"],"financials":null,"yahoo":null}